USA Gov. Birth Control Methods. Available at http://www.womenshealth.gov/faq/birth-control-methods.cfm.

Accessed May 16th, 201

 Injeksi

 Implant
 Cincin Vaginal


Metode Hormonal

Pills)

http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0005085/
“The Patch”
(Kombinasi Oral
Kontrasepsi Oral

Mini/ Progestron Only

http://www.sciencedaily.com/releases/2008/01/080124203037.htm.
Kontrasepsi/ KOK, Pil KB

Accessed June 13th, 2011.

 For Healthcare Professionals only

Contraception - with maintained cycle control2,3

MARVELON regimen
21 days or 28 days

30 g EE Pill free interval

150 g DSG or placebo

21 days 7 days

Marvelon Product Information

Cycle control in MARVELON users
Irregular bleeding

25
spotting BTB
(breakthrough bleeding)
20
percentage

15

10

0
0 1 2 3 4 5 6
cycle (N=11,605)

Adapted from Bilotta and Favilli Arznei Forsch/Drug Res 1988; 38 (II): 932-4
Effect on body weight
weight change (kg) during MARVELON use

70.0%

60.0% MARVELON

30 µg ethinylestradiol /
50.0% 3000 µg drospirenone
% of women

40.0%

30.0%

20.0%

10.0%

0.0%
increase (> 2 kg) stable (± 2 kg) decrease (< 2kg)

Mean Weight loss:

Marvelon - 0.19 kg (n baseline = 412)
30 µg ethinylestradiol/ 3000 µg drospirenone - 0.46 kg (n baseline = 1,657)

Huber, et al. Eur J Contracept Reprod Health Care 2000;5:25–34

Subjective side effects with MARVELON
‘starters’

10

0
nausea headache breast
tenderness

pre -treatment cycle 1 cycle 3 cycle 6

(N=808)
Adapted from Rekers Acta Obstet Gynecol Scand 1988; 67: 171-4
Subjective side effects with MARVELON
‘switchers’

10

0
nausea headache breast
tenderness

pre -treatment cycle 1 cycle 3 cycle 6

(N=685)
Adapted from Rekers Acta Obstet Gynecol Scand 1988; 67: 171-4
The effect of MARVELON on dysmenorrhea
Difference in individual VAS pain scores between triphasic COCs
and MARVELON

250

150

50

-50

-150

-250

-350 (N=22)

-450
The histogram shows the difference in subjective pain evaluation by the patients during use of
monophasic and triphasic oral contraceptives, respectively. Each staple represents one patient.
The ordinate expresses the difference in the total number of millimetres registered on the visual
analogue scale for the whole 3-month period on each type of treatment. Negative values express
less pain during menstruation while on the monophasic pill (MARVELON)

Nabrink et al. Contraception 1990; 42: 275-283

 Difference in PMS between MARVELON
and monophasic LNG
A randomized, double blind cross-over design

Influence on social monophasic LNG Marvelon

and family life

sexuality
*
neg. physical *
negative mood **
positive mood

0 5 10 15 20
mean symptom score
* p<0.05 **p<0.005 (N=37)

Bäckström et al. Contraception 1992; 46: 253-68

Effects on free testosterone
MARVELON vs. 30 EE / 150 LNG

50 MARVELON 150 LNG / 30 EE

Free testosterone pmol/l

40

30
**

20

*
10

0
pretreatment cycle 3

* p<0.001 **p<0.05 (N=10)

Hammond et al. 1984 Fertility and Sterility 1984; 42: 44-51

Effect of MARVELON on
acne and seborrhea

Acne (N=1021) Seborrhea (N=917)

100
90
80
percentage of women

70
60
50
40
30
20
10
0
cycle 3 cycle 6 cycle 3 cycle 6

persistent new absent

Adapted from Bilotta and Favilli 1988 Arznei Forsch/Drug Res 1988; 38 (II): 932-4
Effect on HDL cholesterol
MARVELON vs. LNG

percentage change from baseline

15
**
10

-5
*
-10

-15
**
-20

MARVELON 30 EE / 250 LNG 30 EE / 150 LNG

* p<0.01 ** p<0.001 (N=1,478)

Adapted from: Godsland et al N.Engl.J.Med 1990; 323: 1375-81

Effect on LDL cholesterol
Marvelon vs. LNG

percentage change from baseline

2
0
-2
-4
-6
-8
-10
-12
-14 *

MARVELON 30 EE / 250 LNG 30 EE / 150 LNG

* p<0.01 (N=1,478)

Adapted from: Godsland et al 1990 N.Engl.J.Med 1990; 323: 1375-81

 Conclusions

MARVELON:
 Demonstrated contraceptive reliability1
 Maintained cycle control2,3
 Low incidence of side effects2
 Reduced incidences of dysmenorrhea4
 Reduced symptoms of premenstrual syndrome5
 Negligible effect on body weight6
 Improved pre-existing acne7